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Abstract 
Trastuzumab’s targeted therapy has become a stronghold for human epidermal growth 
factor receptor 2 positive breast cancer patients. This humanized monoclonal antibody 
binds to the extracellular juxta-membrane domain of HER2 and inhibits the proliferation 
and survival of HER2 dependent cancer cells. The ways by which this molecule exerts its 
action have been partially elucidated but several new mechanisms are being constantly 
identified. Several new agents are being introduced that interfere with HER2. Several 
new immunotherapy strategies are being introduced in order to direct the immune sys-
tem against cells and tissues that aberrantly overexpressed HER2. We review the strate-
gies currently adopted and those suggested against HER2 expressing tumors. 
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INTRODUCTION 
HER2 (Human Epidermal growth factor Recep-
tor 2) is a tyrosine kinase receptor of the family that 
includes HER1 (EGFR), HER3 and HER4. This recep-
tor mediates cell differentiation and proliferation in 
both embryonic and adult tissues. More than 30 lig-
ands have been identified that bind epidermal growth 
factor receptor with the exception of HER2, which is 
the  only  deaf  member.  HER2  over-expression  can 
therefore  induce  transformation  in  a  ligand  inde-
pendent way [1]. 
HER2 RECEPTOR 
Prognostic effects of HER2 over-expression in 
breast cancer patients 
 The HER2, also known as neu or c-erbB-2 [2], is a 
proto-oncogene  located  on  the  long  arm  of  human 
chromosome 17 (17 q21-q22) that encodes a protein of 
185 kDa [1, 2]. 
 HER2 activation induces cell proliferation, mi-
gration and differentiation. Furthermore HER2 is in-
volved  in  an  anti-apoptotic  mechanism  and  in  the 
production  of  vascular  epidermal  growth  factor 
(VEGF). All these activities are mediated by two in-
tracellular  pathways  which  include  PI3K  and 
MAP-kinase [3]. 
 In human tissues HER2 gene amplification level 
and protein overexpression can be tested by Fluores-
cence In Situ Hybridization (FISH) and/or immuno-
hystochemistry  (IHC)  respectively,  according  to  the 
guidelines  of  the  American  Society  of  Clinical  On-
cology (ASCO) and College of American Pathologist 
(CAP) (Figure 1) [4].  
Recently  some  authors  advocated  the  use  of 
mRNA dosage as a more adequate diagnostic tool [5]. 
The incidence of HER2 receptor expression, evaluated 
by IHC in different neoplasms is reported in Table 1. 
Ivyspring  
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A  significant  correlation  between  HER2  gene 
overexpression and lymph nodal metastasis has been 
identified  in  breast  cancer.  Furthermore  c-erbB2  is 
associated with drug resistance [12]. 
In  the  absence  of  specific  targeted  therapies 
HER2 gene amplification represents one of the most 
important  negative  prognostic  factors  in  early  and 
advanced breast cancer [6]. 
TRASTUZUMAB 
Trastuzumab and clinical outcome 
 Standard  treatment  for  breast  cancer  patients 
includes  surgery,  chemotherapy,  radiotherapy  and 
hormonal therapy that are administered according to 
clinical, pathological and biological characteristics [13, 
14]. Since 1998 the FDA has approved Trastuzumab 
for the treatment of recurrent HER2 positive BC pa-
tients. Emerging  evidence from large phase III ran-
domized  trials  have  extended  the  indications  of 
Trastuzumab to the vast majority of IHC triple posi-
tive or FISH positive HER2 patients. Briefly the results 
of the most relevant clinical trials are summarized in 
Table 2. 
 
 
 
 
Figure 1. HER2 testing algorithm. Modified from Hanna MW, Mod Pathol 2006. 
 
 
 
Table 1. HER2 overexpression in different neoplasms 
AUTHORS  TYPE OF NEOPLASMS  IHC HER2-OVEREXPRESSION (%) 
Slamon et al. [6]  Breast cancer  30% 
Slamon et al. [7]  Ovarian cancer  25-30% 
Hofmann M et al. [8]  Gastric cancer  7-34% 
Santin et al. [9]  Endometrial cancer  10% 
Liu et al. [10]  Lung cancer  9% 
Langner et al. [11].  Urinary tract transitional cells carcinoma  0-10% 
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Table 2. Results of clinical trials  
CLINICAL TRIALS 
Slamon DJ et al. [15]  METASTATIC 
BREAST 
CANCER 
CT alone  20.1 median OS  p=0,046 
CT plus Trastuzumab  25.1 median OS 
Romond EH et al. [16]   
 
EARLY STAGES 
LOCALLY 
INVASIVE 
BREAST 
CANCER 
CT alone  86.6% OS at 4 years  p=0,015 
CT plus Trastuzumab  91.4% OS at 4 years 
Piccart-Gebhart MJ et al. [17]  CT alone  95.1% OS at 2 years  p=0,26 
CT plus Trastuzumab  96% OS at 2 years 
Smith I et al. [18]  CT alone  89.4% OS at 2 years  p=0,005 
CT plus Trastuzumab  92.4% at 2 years 
OS=overall survival 
 
Trastuzumab Mechanisms of Action 
The ways through which Trastuzumab exerts its 
antitumor activity have not yet been completely un-
revealed, however certain extracellular and intracel-
lular mechanisms have been identified. 
Intracellular action: 
By  blocking  dimerization,  Trastuzumab  inter-
feres  with  the  activity  of  the  intracellular  signaling 
activated by HER2 in healthy and mostly neoplastic 
tissues. This effect plays its role by inhibiting DNA 
damage repair, inducing cell cycle arrest and inhibit-
ing tumor angiogenesis.  
Trastuzumab  decreases  expression  of 
p21/WAF1 and promotes early escape from G1 phase 
inducing accumulation of DNA damage and apopto-
sis [19]. This MoAb modulates the phosphorylation of 
p27Kip1 [20], protein involved in cell-cycle arrest in G1 
phase  [21].  It  decreases  survivin  levels  with  conse-
quently reduction in apoptosis resistance [22]. In ad-
dition  Trastuzumab  reduces  VEGF  secretion  and 
therefore angiogenesis in neoplastic tissues.  
Extracellular action: 
 Trastuzumab plays its activity also through its 
antibody characteristics which affect the immunolog-
ical control of neoplastic cells, islet and tissues. In re-
cent years abundant evidences have demonstrated the 
pivotal role of the immune system on tumorogenesis 
and tumor progression in several different neoplasms 
[23-26]. 
 Anti-HER2 MoAb activates both the innate and 
the adaptive immune system. The effect on the innate 
immune  system,  in  particular  Natural  Killer  (NK) 
cells, is mediated by Fc portion. In vitro and in vivo 
evidences  have  clearly  demonstrated  that  this  anti-
body is able to induce granzyme release with conse-
quent tumor cells killing [27]. In addiction the effect of 
IFNγ released by activated NK cells is potentiated by 
the  intracellular  anti-apoptotic  effect  mediated  by 
STAT1 [28]. 
 A less intuitive but possibly important mecha-
nisms  are  mediated  by  adaptive  immune  system. 
Trastuzumab-HER2  complexes  are  most  rapidly  in-
ternalized, thus HER2 undergoes to an increased in-
tracellular degradation with a consequent production 
of  HER2  epitopes.  HLA  class  I  molecules  can  be 
loaded with these HER2 fragment, allowing lysis of 
tumor cells by specific CTLs [29]. 
 So far, it has been reported that Trastuzumab is 
able to induce a long lasting immune response [30], 
reduce circulating T regulatory cells (Tregs) [31] and 
alter the balance between Tregs and Th17 [32].  
Lastly, apoptosis induced by NK cells generates 
apoptotic bodies which are easily fagocitated by APCs 
thereby increasing the number of specific antitumor 
circulating  CTLs  [33].  It  is  therefore  evident  how 
Trastuzumab not only activates the adaptive immune 
system against HER2 but represents an effective tool 
that determines also epitope spreading. 
Resistance to Trastuzumab 
 Mechanisms  involved  to  Trastuzumab  re-
sistance  are  HER2  mutation,  cross-talk  among  the 
other extracellular HER proteins that induces incom-
plete  inhibition  of  target  receptor  [34],  masking  of 
HER2 proteins mediated by MUC1/MUC4 glycopro-
tein  (MUC1/MUC4)  [35],  inhibition  of  insulin-like 
growth factor [36] and tensin homologue (PTEN) de-
ficiency [37].  
NOVEL STRATEGIES 
New anti-HER2 strategies  
 A detailed description of all tyrosine kinase in-
hibitors which block the intracellular pathways acti-
vated by HER2 is beyond this review’s objectives. As Journal of Cancer 2011, 2 
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follow, this is a brief description of the most important 
and promising drugs that have been introduced both 
to increase the effect of Trastuzumab and to bypass 
the mechanisms of resistance. 
 Lapatinib,  a  dual  tyrosine  kinase  inhibitor 
(EGFR/HER1 and HER2), is the only targeted therapy 
other  Trastuzumab  approved  by  FDA  for 
HER2-positive metastatic breast cancer patients. This 
small  molecule  works  by  competing  with  ATP  for 
binding sites on intracellular portions of HER1/HER2 
and targets the downstream ERK1-2 and PIK3-AKT 
pathways, which regulate cells proliferation and sur-
vival, respectively [38]. The role of Lapatinib in dif-
ferent treatment settings (neoadjuvant, adjuvant and 
metastatic) is being defined by ongoing trials. Differ-
ently  from  Trastuzumab,  Lapatinib  stabilizes  the 
HER2 receptor on the cells surface thereby increasing 
the effect of Trastuzumab and consequent NK activi-
ty. On-going analysis on the immunological effect of 
Lapatinib are currently carried out by our group. 
 Some new agents such as tyrosine kinase (TKIs), 
VEGF and mTOR inhibitors, T-DM1, alvespspimycin 
(HSP90 inhibitor) and poly ADP-ribose polymerase-1 
(PARP-1) inhibitors seem to have a theoretical benefit, 
but results on clinical trials that can define a role in 
treatment of Trastuzumab-resistant BC, are still una-
vailable (Table 3, Table 4) [39]. 
 
Table 3. Dual targeting agents in development 
AGENT  TARGET  STAGE OF DEVELOPMENT  IRREVERSIBLE 
BINDING 
Tyrosine kinase inhibitors 
Lapatinib  EGFR/HER1, HER2  Phase III breast and kidney cancer  No 
BIBW-2992  EGFR/HER1, HER2  Phase II prostate  Yes 
HKI-272  EGFR/HER1, HER2  Phase II breats and NSCLC  Yes 
CI-1033  EGFR/HER1, HER2, HER 4  Phase II breast and NSCLC  Yes 
Monoclonal antibodies 
Pertuzumab   EGFR/HER1, HER2, HER 4  Phase II ovarian, NSCLC, breast and prostate  ? 
 
 
Table 4. Agents developed vs HER2-resistant breast cancer 
AGENT  MECHANISM OF ACTION  PHASE OF CLINICAL 
DEVELOPMENT 
VACCINES 
E75  Activate cytotoxic T lymphocytes that identify HER2 cancer 
cells, leading to cell death 
1,2 
GP2  Activate cytotoxic T lymphocytes that identify HER2 cancer 
cells, leading to cell death 
2 
AF37, li-Key  Direct antigenic epitope charging of HLA class II molecules on 
the cell surface 
2 
NEW COMPOUNDS 
T-DM1  Trastuzumab conjugated with maytansine to improve potency  1,2,3 
KU-0059436 (Ku)  PARP inhibitor  1,2 
Pertuzumab  Inhibits heterodimerization of HER2 and other EGFRs  1,2,3 
Ertumaxomab  Biospecific monoclonal antibody that blcks HER2 and CD3  2 
Neratinib  Irreversible pan-ERBB inhibitor  1,2,3 
Tanespimycin  HSP90 inhibitor  1,2 
Alvespimycin  HSP90 inhibitor  1,2 
Temsirolimus  mTOR inhibitor  1,2,3 
Everolimus  mTOR inhibitor  1,2 
Pazopanib  Multitargeted inhibitor of VEGFR, PDGFR and c-KIT  1,2 
SIGNAL-TRANSDUCTION INHIBITION 
Anastrozole + trastuzumab  Aromatase inhibitor plus HER2 inhibition  2,3 
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Adjuvant vaccine immunotherapy 
The  relationship  between  cancer,  cancer  treat-
ments and the immune system is extremely complex. 
Oncological procedures can activate or modulate an 
immune response [40, 41]. Furthermore the immune 
effect of different treatments depends on the timing of 
administration [25,42]. 
 Researchers  world-wide  are  investigating  sev-
eral new families of antigens in female tumors [43-46]. 
HER2 is one of the most studied targets for active 
immunotherapy.  Several  highly  immunogenic 
epitopes have been identified; furthermore some in-
teresting non randomized clinical data have strongly 
suggested a clinical efficacy when anti-HER2 peptide 
vaccination is carried out in a particular setting [47]. 
To  be  effective,  simple  peptide  vaccination  re-
quires to be administered in patients with a compe-
tent  immunological  system.  The  immune  system  of 
women with high tumor burden suffers from an im-
mune  suppressed  status  especially  due  to  a  high 
proportion of regulatory T cells (Tregs) [25]. 
For this latter group more complex strategies are 
required in order to guarantee an immune effective 
response.  
Currently some trials have been carried out us-
ing E75 and GP2 HER2 peptides. There are strongly 
suggestive  data  to  demonstrate  a  synergistic  effect 
between  peptide-vaccination  and  the  use  of 
Trastuzumab [48]. 
More complex methods to induce a immune re-
sponse  include  the  use  of  fusion  proteins  primary 
constituted by a combination of multiple highly anti-
genic HER2 epitopes fused to the Fc domain of human 
IgG1. The rational of this approach is to specifically 
load  the  APC  expressing  the  Fc  receptors  with  the 
HER2 antigen, increasing antigen uptake, processing 
and epitope presentation.  
A third step forward has been developed in a 
pre-clinical setting using micro-vesicles derived from 
HER2 transfected cell limphoblastoid cell line carry-
ing  HLAI/peptide  complexes  and  co-stimulatory 
molecules.  These  vesicles  can  be  utilized  to  pulse 
dendritic cells (DCs) and achieve very potent active 
anti  tumor  immune  responses  [49].  Both  these  ap-
proaches can be employed despite the HLA haplotype 
of the patients, in fact DCs are loaded with long do-
main of HER protein, thus enabling the DCs to gen-
erate a patient tailored repertoire of HER2 epitopes. 
Recently  DCs  therapy  have  been  approved  by 
FDA for the treatment of prostatic cancer [50, 51]. One 
of the most recent avenues that are being pursued is 
the use of DCs. Cell therapy remains extremely com-
plex and the quality of cells produce strictly depends 
on methods and materials adopted [52]. 
Currently  some  preliminary  experiences  on 
DCs-vaccination pulsed with HER2 peptides are pre-
sent in literature. Of our interest will be the results of 
phase  II  randomized  trial  which  will  evaluate  the 
safety  and  indirectly  the  immunological  efficacy  of 
two DCs vaccination administration strategies. 
CONCLUSIONS 
 HER2 currently represents the most important 
biological  target  in  the  clinical  practice  for  breast 
cancer  patients.  Trastuzumab  plays  its  role  both 
through  immunological  and  intracellular  mecha-
nisms. Currently new drugs that target this receptor 
or its intracellular pathways are available and already 
employed  in  clinical  settings.  On  the  other  hand, 
HER2  targeting  strategies  exert  an  important  side 
effect  on  immunesurveillance,  activating  anti  HER2 
specific  immune  response  and  enhancing  epitope 
spreading.  The  integration  of  immune  vaccination 
strategies within the standard therapeutic framework 
can be an optimal and an efficacious approach to in-
duce and maintain a long lasting anti-tumor immune 
response. 
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